DNA

Helio Genomics and Halub Medical Co. Announce Strategic Partnership to Commercialize HelioLiver Dx in The Gulf Cooperation Council and Middle East

IRVINE, Calif., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Helio Genomics (“Helio” or “the Company”), an AI-driven biotechnology company specializing in…

1 year ago

Trinity Biotech Enters Oncology Space with Acquisition of Prostate Cancer Focused EpiCapture

DUBLIN, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB), a commercial-stage biotechnology company focused on human diagnostics…

1 year ago

Tonix Pharmaceuticals to Present at the 2024 ThinkEquity Conference

CHATHAM, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated…

1 year ago

Rakovina Therapeutics to Present Research Highlighting Small-Molecule Bifunctional Inhibitors of PARP1/2 and HDAC Enzymes at the 36th EORTC-NCI-AACR Symposium in Barcelona Spain

VANCOUVER, British Columbia, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”), a biopharmaceutical…

1 year ago

ANI Pharmaceuticals Announces the FDA Approval and Launch of Estradiol Gel, 0.06%

PRINCETON, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that…

1 year ago

Ayana Bio to Showcase Plant Cell Advantage™ Health & Wellness Ingredients at SupplySide West 2024

Ayana Bio's NeuroAdvantage and ImmunAdvantage prototypes will be available at SupplySide West booth #7071. BOSTON, Oct. 24, 2024 /PRNewswire/ --…

1 year ago

Leading HIM & Coding Vendors Driving Breakthrough Innovation, Setting the Pace for Industry Transformation, Reports Black Book Survey

Top medical coding and HIM solutions, recognized by clients and system users among the best in the industry, will showcase…

1 year ago

BioCryst Presents New Real-World Evidence Showing High Adherence and Persistence Rates with ORLADEYO® (berotralstat)

Additional real-world studies show sustained HAE attack rate reduction after initiating ORLADEYO, regardless of C1-INH status, and patient preference for…

1 year ago